These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 19296065)

  • 1. [Possibilities and risks of the monoclonal antibody alemtuzumab as a new treatment option for multiple sclerosis].
    Warnke C; Kieseier BC; Zettl U; Hartung HP
    Nervenarzt; 2009 Apr; 80(4):468-74. PubMed ID: 19296065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alemtuzumab and multiple sclerosis: therapeutic application.
    Minagar A; Alexander JS; Sahraian MA; Zivadinov R
    Expert Opin Biol Ther; 2010 Mar; 10(3):421-9. PubMed ID: 20095876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoclonal antibodies in the treatment of multiple sclerosis.
    Di Pauli F; Berger T; Reindl M
    Curr Med Chem; 2009; 16(36):4858-68. PubMed ID: 19929782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specific immune intervention with monoclonal antibodies for the treatment of multiple sclerosis.
    Trebst C; Voss E; Skripuletz T; Stangel M
    Curr Med Chem; 2010; 17(7):640-50. PubMed ID: 20088763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spotlight on alemtuzumab.
    Jones JL; Coles AJ
    Int MS J; 2009 Sep; 16(3):77-81. PubMed ID: 19878629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Alemtuzumab in early multiple sclerosis].
    Killestein J; Polman CH
    Ned Tijdschr Geneeskd; 2009 Jan; 153(1-2):46. PubMed ID: 19198214
    [No Abstract]   [Full Text] [Related]  

  • 7. Monoclonal antibody treatments for multiple sclerosis.
    Rose JW; Foley J; Carlson N
    Curr Neurol Neurosci Rep; 2008 Sep; 8(5):419-26. PubMed ID: 18713579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Biological treatment of multiple sclerosis].
    Sørensen PS; Sellebjerg F
    Ugeskr Laeger; 2008 Jun; 170(24):2156-9. PubMed ID: 18565303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort.
    Cossburn M; Pace AA; Jones J; Ali R; Ingram G; Baker K; Hirst C; Zajicek J; Scolding N; Boggild M; Pickersgill T; Ben-Shlomo Y; Coles A; Robertson NP
    Neurology; 2011 Aug; 77(6):573-9. PubMed ID: 21795656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoclonal antibodies in treatment of multiple sclerosis.
    Rommer PS; Dudesek A; Stüve O; Zettl UK
    Clin Exp Immunol; 2014 Mar; 175(3):373-84. PubMed ID: 24001305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging monoclonal antibody therapies for multiple sclerosis.
    Cree B
    Neurologist; 2006 Jul; 12(4):171-8. PubMed ID: 16832236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Melanoma following treatment with alemtuzumab for multiple sclerosis.
    Pace AA; Zajicek JP
    Eur J Neurol; 2009 Apr; 16(4):e70-1. PubMed ID: 19222552
    [No Abstract]   [Full Text] [Related]  

  • 13. Alemtuzumab (Millennium/ILEX).
    Dumont FJ
    Curr Opin Investig Drugs; 2001 Jan; 2(1):139-60. PubMed ID: 11527007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H).
    Jones JL; Phuah CL; Cox AL; Thompson SA; Ban M; Shawcross J; Walton A; Sawcer SJ; Compston A; Coles AJ
    J Clin Invest; 2009 Jul; 119(7):2052-61. PubMed ID: 19546505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical trials with CAMPATH-I and other monoclonal antibodies.
    Hale G; Phillips JM
    Biochem Soc Trans; 1995 Nov; 23(4):1057-63. PubMed ID: 8654681
    [No Abstract]   [Full Text] [Related]  

  • 16. Treating multiple sclerosis with monoclonal antibodies.
    Buttmann M; Rieckmann P
    Expert Rev Neurother; 2008 Mar; 8(3):433-55. PubMed ID: 18345973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Development of new therapies for multiple sclerosis].
    Holmøy T; Celius EG
    Tidsskr Nor Laegeforen; 2011 May; 131(8):832-6. PubMed ID: 21556088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond.
    Ruck T; Bittner S; Wiendl H; Meuth SG
    Int J Mol Sci; 2015 Jul; 16(7):16414-39. PubMed ID: 26204829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Therapeutic monoclonal antibodies in clinical neurology].
    Buttmann M; Wiendl H
    Nervenarzt; 2010 Jun; 81(6):753-64; quiz 765-6. PubMed ID: 20232033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alemtuzumab in the treatment of relapsing-remitting multiple sclerosis.
    Fox EJ
    Expert Rev Neurother; 2010 Dec; 10(12):1789-97. PubMed ID: 21091310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.